Skip to search boxSkip to navigationSkip to main content

Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit

  • Michael T. Richardson
    ,
  • David P. Mysona
    ,
  • David A. Klein
    ,
  • Amandeep Mann
    ,
  • Cheng I. Liao
    ,
  • Elisabeth J. Diver
*Corresponding author for this work
  • Stanford University
    ,
  • University of North Carolina at Chapel Hill
    ,
  • University of California at San Francisco
    ,
  • Palo Alto Medical Foundation
    ,
  • Veterans General Hospital-Kaohsiung Taiwan
    ,
  • Walter Reed Army Institute of Research
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Objectives: To determine the long-term potential benefit of adjuvant chemotherapy in subgroups of high-risk stage I mucinous ovarian cancer patients using a predictive scoring algorithm. Methods: Data were collected from the National Cancer Database from 2004 to 2014. Based on demographic and surgical characteristics, a novel 10-year survival prognostic scoring system was developed using Cox regression. Results: There were 2041 eligible patients with stage I mucinous ovarian cancer including 1362 (67%) with stage IA/IB disease, 598 (29%) with stage IC disease, and 81 (4%) with stage I disease not otherwise specified. Median age was 52 with a range of 13–90 years old. 737 (36%) patients were treated with adjuvant chemotherapy. Adjuvant chemotherapy was more common in patients with stage IC relative to stage IA/IB disease (69% vs. 21%, P < 0.001) or with poorly-differentiated relative to well-differentiated tumors (69% vs. 23%, P < 0.001). Unadjusted 10-year survival was 81% relative to 79% for patients treated with vs. without chemotherapy, respectively (P = 0.46). Patients were predicted to exhibit a low- or a high-risk of death using a multivariate Cox regression model with age, stage, grade, lymphovascular space invasion and ascites. Risk of death without vs. with adjuvant chemotherapy was similar in low-risk patients (88% vs. 84%; HR = 0.80, 95%CI = 0.56–1.15, P = 0.23) and worse in high-risk patients (51% vs. 74%; HR = 1.58, 95%CI: 1.05–2.38, P = 0.03) with stage I mucinous ovarian cancer. Conclusions: A predictive scoring algorithm may provide prognostic information on long-term survival and identify high-risk stage I mucinous ovarian cancer patients who might achieve a survival benefit from adjuvant chemotherapy.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 118-128 (11 pages)

Journal (Volume, Issue Number)

Gynecologic Oncology (Volume 159, Issue 1)

Publication milestones

  • Published - 10/2020

Publication status

Published - 10/2020

ISSN

0090-8258

Publication IDs

  • Scopus: 85089557956
  • PubMed: 32828578

Publication metrics

Metrics

Fractional count
2
Fractional count
0.15
Fractional count
11
Fractional count
0.85
Fractional count
2
Fractional count
1
SciVal
Author count
13
SciVal
Paper percentile
50
Scopus
citations

PlumX, opens in new tab

Captures
16
Citation count
13

Funding Details

This research was supported by the Denise Cobb Hale and Fisher Family Fund .
FunderFunding numbers
Denise Cobb Hale and Fisher Family Fund
-